WikiJournalClub:Usable articles
The following are articles in Category:Usable articles.
Allergy and Immunology
Asthma
- EXTRA (2011): Omalizumab in severe allergic asthma
Cardiology
Acute Coronary Syndrome
- ACT (2011): Acetylcysteine with IV contrast
- ATLAS ACS-2, TIMI 51 (2012): Rivaroxaban after ACS
- CAPRICORN (2001): Carvedilol post-MI with HFrEF
- CAST I (1991): Antiarrhythmics post-MI
- CHAMPION PHOENIX (2013): Cangrelor during urgent or elective PCI
- CHARISMA (2006): Aspirin/clopidogrel vs. aspirin for CV prevention
- COLCOT (2019): Colchicine vs. placebo in ACS
- COMMIT (2005): Metoprolol in acute MI
- CURE (2001): Clopidogrel in UA/NSTEMI
- EPHESUS (2003): Eplerenone post-MI with HFrEF
- ESSENCE (1997): LMWH vs. UFH in UA/NSTEMI
- FRISC-II (1999): Early invasive strategy in UA/NSTEMI
- GISSI-3 (1994): Lisinopril in acute MI
- GUSTO (1993): tPA in ACS
- HS troponin-T to rule out MI (2014): High sensitivity troponin for acute chest pain
- IABP-SHOCK II (2012): IABP in MI and cardiogenic shock
- IMPROVE-IT (2015): Ezetimibe+simvastatin after ACS
- ISIS-2 (1988): Aspirin ± streptokinase in acute MI
- MADIT-II (2002): ICD post-MI with HFrEF
- MIRACL (2001): Atorvastatin in UA/NSTEMI
- OASIS-5 (2006): Fondaparinux vs. enoxaparin in NSTE-ACS
- OAT (2006): PCI+OMT vs. OMT 3-28 days after MI
- PEGASUS-TIMI 54 (2015): Extended ticagrelor+ASA after MI
- PIONEER AF-PCI (2016): DOAC, VKA, antiplatelets after PCI with stent
- PLATO (2009): Ticagrelor vs. clopidogrel in ACS
- PROVE IT-TIMI 22 (2004): Pravastatin vs. atorvastatin after ACS
- REALITY (2021): Transfusion thresholds in MI
- SADHART (2002): Sertraline for depression post-ACS
- SAVE (1992): Captopril in MI with LV dysfunction
- SHOCK (1999): Early PCI/CABG in MI + shock
- TIMACS (2009): Early vs. delayed PCI in NSTEMI and UA
- TRITON-TIMI 38 (2007): Prasugrel vs. clopidogrel in ACS
- VA Cooperative Study (1983): Aspirin in unstable angina
- VALIANT (2003): Valsartan vs. captopril in MI with LV dysfunction
Acute Kidney Injury
- ACT (2011): Acetylcysteine with IV contrast
Anemia
- RED-HF (2013): Darbepoetin in HFrEF
Aortic Stenosis
- Evolut Low Risk (2019): TAVR in low-risk patients
- PARTNER 2 (2016): TAVI for AS in intermediate-risk surgical candidates
- PARTNER 3 (2019): TAVR for AS in low-risk surgical candidates
- PARTNER A (2011): TAVI for AS in high-risk surgical candidates
- PARTNER B (2010): TAVI for AS in poor surgical candidates
- SURTAVI (2017): TAVI for AS in intermediate-risk surgical candidates
Atherosclerotic Coronary Artery Disease
- ASPREE (2018): Aspirin for ASCVD 1° prevention if age >70
Atrial Fibrillation
- AATAC (2016): AF ablation vs. amiodarone in HFrEF with LVEF ≤40%
- ACTIVE A (2009): ASA/clopidogrel vs. ASA in AF
- ACTIVE W (2006): ASA/clopidogrel vs. warfarin in AF
- AFFIRM (2002): Rate vs. rhythm control in AF
- ARISTOTLE (2011): Apixaban vs. warfarin in AF
- ARTESIA (2023): Apixaban vs. aspirin in subclinical AF
- AUGUSTUS (2019): DOAC, VKA, antiplatelets after PCI with stent and AF
- AVERROES (2011): Apixaban vs. ASA in AF
- BRIDGE (2015): LMWH bridging for surgery in AF
- CABANA (2019): Catheter ablation vs. anti-arrhythmic therapy in AF
- CASTLE-AF (2018): Catheter ablation vs. standard therapy in AF+HF
- EARLY-AF (2021): Cryoablation vs. antiarrhythmics in AF
- EAST-AFNET 4 (2020): Early rhythm vs. rate control in AF
- EMBRACE (2014): Extended EKG monitoring after cryptogenic stroke
- ENGAGE AF-TIMI 48 (2013): Edoxaban vs. warfarin in AF
- EPIC-CAD (2024): Edoxaban±antiplatelet in AF+stable CAD
- FIRE AND ICE (2016): Cryoablation vs. RF ablation in pAF
- ISAR-TRIPLE (2015): Triple therapy for 6w vs. 6m after DES
- ORBIT-AF (2013): ASA/warfarin vs. warfarin in AF
- PAUSE (2019): Perioperative DOAC holding protocols in AF
- PREVAIL (2014): LAA closure vs. warfarin in AF
- PROTECT AF (2009): LAA closure vs. warfarin in AF
- RACE II (2010): Lenient vs. strict rate control in AF
- RE-LY (2009): Dabigatran vs. warfarin in AF
- ROCKET AF (2011): Rivaroxaban vs. warfarin in AF
- SPAF (1991): Aspirin and warfarin in AF
Atrioventricular Block
- BLOCK-HF (2013): RV pacing vs. BiV pacing in HF with AV block
Bradycardia
- DAVID (2002): Dual-chamber vs. ventricular backup pacing in ICD patients
- MOST (2002): Dual- vs. single-chamber pacing in bradycardia
Cancer
- VITAL (Omega-3 arm) (2019): Omega-3 FA for CV and cancer prevention
- VITAL (Vitamin D arm) (2019): Vitamin D for cancer or CVD prevention
Cardiac Arrest
- HACA (2002): Hypothermia for cardiac arrest
- TTM (2014): 33 vs. 36°C body temperature after cardiac arrest
- TTM2 (2021): 33°C vs. normothermia after cardiac arrest
Cardiac Risk Assessment
- CARP (2004): Preop coronary revascularization if stable CAD
- POISE (2008): Perioperative metoprolol
- POISE-2 ASA (2014): Perioperative ASA
Cardiogenic Shock
- DanGer Shock (2024): Impella in STEMI w/cardiogenic shock
Cardiovascular Disease
- AURORA (2009): Rosuvastatin in ESRD
- CHARISMA (2006): Aspirin/clopidogrel vs. aspirin for CV prevention
- CORAL (2014): Stenting vs. medical therapy in RAS
- HOPE-3 (2016): Statin, BP meds, both, or neither for CVD 1° prevention
- HPS Statin (2002): Simvastatin in high risk for CVD
- LEADER (2016): Liraglutide and CVD endpoints in T2DM
- Look AHEAD (2013): Weight loss and exercise in T2DM
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
- ORIGIN n-3 Fatty Acids (2012): Fish oil for high-risk CVD
- SUSTAIN-6 (2016): GLP-1 in DM if high CVD risk
- VITAL (Omega-3 arm) (2019): Omega-3 FA for CV and cancer prevention
- VITAL (Vitamin D arm) (2019): Vitamin D for cancer or CVD prevention
Cardiovascular disease
- SELECT (2023): GLP-1 if prior CVD, BMI ≥27, no DM
Carotid Stenosis
- ACT I (2016): Carotid stenting vs. endarterectomy
- CREST (2010): Stenting vs. CEA in carotid stenosis
Chronic Kidney Disease
Coronary Artery Disease
- 4S (1994): Simvastatin in stable CAD
- ACCORD Lipid (2010): Fibrate add-on to statins in T2DM
- AIDA (2017): Scaffold vs. stent in PCI
- ALLHAT-LLT Elderly (2017): Pravastatin vs usual care for ASCVD primary prevention
- ART (2019): Bilateral vs. single IMA graft in multivessel CAD
- ATLAS ACS-2, TIMI 51 (2012): Rivaroxaban after ACS
- BARI 2D (2009): CABG/PCI vs. OMT in diabetes with CAD
- BEST (2015): PCI vs. CABG for multivessel disease
- CANTOS (2017): Canakinumab in patients with previous MI
- CAPRIE (1996): Clopidogrel vs. aspirin in CV disease
- CARP (2004): Preop coronary revascularization if stable CAD
- CHAMPION PHOENIX (2013): Cangrelor during urgent or elective PCI
- COGENT (2010): PPI plus clopidogrel in CAD
- Compare-Acute (2017): Multivessel PCI vs. FFR-guided complete revascularization
- COMPASS (2017): Rivaroxaban, ASA, or both in stable CAD
- COURAGE (2007): PCI vs. medical therapy in CAD
- CULPRIT-SHOCK (2017): Culprit-only vs. multivessel PCI in cardiogenic shock
- CvLPRIT (2015): Culprit lesion-only vs. complete revascularization
- DANAMI-3 PRIMULTI (2015): Culprit lesion PCI vs. FFR in multivessel CAD
- DAPT (2014): Aspirin/clopidogrel duration after PCI
- DIVA (2018): BMS vs. DES for saphenous vein graft PCI
- EPIC-CAD (2024): Edoxaban±antiplatelet in AF+stable CAD
- EUROPA (2003): Perindopril in patients with stable CAD
- EXCEL (2016): CABG vs. PCI in left main CAD
- FAME (2009): FFR-guided PCI in stable CAD
- FAME 2 (2012): FFR-guided PCI vs. OMT in CAD
- FOURIER (2017): Evolocumab for CVD events if atherosclerotic disease
- FREEDOM (2012): CABG vs. PCI for CAD in T2DM
- FRISC-II (1999): Early invasive strategy in UA/NSTEMI
- HEAT-PPCI (2014): Heparin vs. bivalirudin in PCI
- HOPE (2000): Ramipril in patients with high CV risk
- HPS2-THRIVE (2014): Niacin in atherosclerotic disease
- IFR-SWEDEHEART (2017): iFR vs. FFR for PCI
- ISAR-REACT 5 (2019): Ticagrelor vs. prasugrel in ACS
- ISAR-TRIPLE (2015): Triple therapy for 6w vs. 6m after DES
- ISCHEMIA (2020): PCI/CABG vs. medical therapy in stable CAD
- JUPITER (2008): Rosuvastatin for primary CV prevention
- LoDoCo (2013): Colchicine for stable CAD
- LoDoCo2 (2020): Colchicine in stable CAD
- MASTER DAPT (2021): Abbreviated DAPT in high-risk bleeding
- MATRIX Antithrombin (2015): Heparin vs. bivalirudin in PCI
- MIRACL (2001): Atorvastatin in UA/NSTEMI
- MRFIT (1982): CHD risk modification for CHD mortality prevention
- NORSTENT (2016): Drug-eluting stent vs. bare-metal stent in CAD
- OAT (2006): PCI+OMT vs. OMT 3-28 days after MI
- ORBITA (2017): PCI vs. medical therapy in stable angina
- ORIGIN n-3 Fatty Acids (2012): Fish oil for high-risk CVD
- PEGASUS-TIMI 54 (2015): Extended ticagrelor+ASA after MI
- PIONEER AF-PCI (2016): DOAC, VKA, antiplatelets after PCI with stent
- PLATO (2009): Ticagrelor vs. clopidogrel in ACS
- POISE (2008): Perioperative metoprolol
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
- PREDIMED (2013): Mediterranean diet in CVD prevention
- RE-DUAL (2017): Triple therapy vs. ASA+dabigatran in PCI if AF
- REDUCE-IT (2018): Icosapent ethyl in CAD
- STICH (2011): CABG in ischemic HFrEF
- SYNTAX (2009): PCI vs. CABG in severe CAD
- TACTICS-TIMI 18 (2001): Early vs. Delayed PCI for UA-NSTEMI
- TIMACS (2009): Early vs. delayed PCI in NSTEMI and UA
- TNT (2005): Atorvastatin in stable CAD
- WOEST (2013): Clopidogrel ± ASA after PCI if on OAC
- WOSCOPS (1995): Pravastatin in CAD
Coronary artery disease
- AUGUSTUS (2019): DOAC, VKA, antiplatelets after PCI with stent and AF
- CIRT (2018): Low-dose MTX for secondary prevention of CAD
Deep Vein Thrombosis
- MARINER (2017): Rivaroxaban VTE ppx after medical admission
Depression
- SADHART (2002): Sertraline for depression post-ACS
Diabetes
- ASCEND (Aspirin) (2018): Aspirin for vascular disease prevention in DM
Diabetes Mellitus
- ACCORD Lipid (2010): Fibrate add-on to statins in T2DM
- BARI 2D (2009): CABG/PCI vs. OMT in diabetes with CAD
- CANVAS (2017): Canagliflozin for CV outcomes in T2DM
- EMPA-REG OUTCOME (2015): Empagliflozin for CV outcomes in T2DM
- FREEDOM (2012): CABG vs. PCI for CAD in T2DM
- LEADER (2016): Liraglutide and CVD endpoints in T2DM
- Look AHEAD (2013): Weight loss and exercise in T2DM
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
- SUSTAIN-6 (2016): GLP-1 in DM if high CVD risk
Dilated Cardiomyopathy
- TRED-HF (2018): Withdrawal of medications in dilated cardiomyopathy
Endocarditis
- EASE (2012): Early surgery in endocarditis
Heart Failure
- A-HeFT (2004): ISDN/hydralazine for black patients with HFrEF
- AATAC (2016): AF ablation vs. amiodarone in HFrEF with LVEF ≤40%
- ADVOR (2022): Acetazolamide vs. placebo in acute HF
- AF-CHF (2008): Rhythm control for AF in HFrEF
- ATTR-ACT (2018): Tafamidis vs. placebo in amyloid cardiomyopathy
- B-CONVINCED (2009): Beta-blocker withdrawal in ADHF
- CARRESS-HF (2012): Ultrafiltration in decompensated HF
- CHARM-Added (2003): ARB plus ACE-I in HF
- CHARM-Alternative (2003): ARBs in HFrEF
- CHARM-Preserved (2003): ARBs in HFpEF
- CIBIS-II (1999): Bisoprolol in HFrEF
- COMET (2003): Carvedilol vs. metoprolol in HFrEF
- CONSENSUS (1987): Enalapril in severe HFrEF
- COPERNICUS (2002): Carvedilol in HFrEF
- CORONA (2007): Rosuvastatin in ischemic HFrEF
- DAPA-HF (2019): Dapagliflozin in HFrEF
- DEFINITE (2004): ICD vs. medical therapy in HFrEF
- DELIVER (2022): Dapagliflozin in HFmrEF or HFpEF
- DIG (1997): Digoxin in HFrEF
- DINAMIT (2004): ICD for ICM shortly after MI
- DONATE-HCV (2019): Donor HCV positive heart and lung transplant
- DOSE (2011): Diuretic dosing in acute HF
- EMPEROR-Preserved (2021): Empagliflozin in HFmrEF and HFpEF
- EMPHASIS-HF (2011): Eplerenone in HFrEF
- EPHESUS (2003): Eplerenone post-MI with HFrEF
- ESCAPE (2005): PA catheters in acute HF management
- EVEREST-Outcomes (2007): Tolvaptan in acute HF in HFrEF
- FAIR-HF (2009): Parenteral iron in HFrEF with iron deficiency
- HEARTMATE II (2009): Continuous-flow LVAD in heart failure
- IRONOUT-HF (2017): Oral iron vs. placebo in HFrEF and iron deficiency
- MADIT-CRT (2009): CRT in HFrEF with QRS ≥130 msec and mild symptoms
- MADIT-II (2002): ICD post-MI with HFrEF
- MERIT-HF (1999): Metoprolol in HFrEF
- MOMENTUM 3 (2018): Centrifugal-flow LVAD vs. axial-flow LVAD in advanced HF
- NEAT-HFpEF (2015): Nitrates for activity tolerance in HFpEF
- PARADIGM-HF (2014): ARNI vs. enalapril in HFrEF
- PARAGON-HF (2019): ARNI in symptomatic HFpEF
- PIONEER-HF (2018): ARNI started in ADHF hospitalization
- RAFT (2010): CRT+ICD for mild-moderate HFrEF
- RALES (1999): Spironolactone in HFrEF
- RED-HF (2013): Darbepoetin in HFrEF
- RELAX (2013): Sildenafil vs. placebo in HFpEF
- REMATCH (2001): Destination LVAD in end-stage heart failure
- SAVE (1992): Captopril in MI with LV dysfunction
- SCD-HeFT (2005): Amiodarone or ICD in severe HFrEF
- SHIFT (2010): Ivabradine in HFrEF
- SOLVD (1991): Enalapril in moderate-severe HFrEF
- STICH (2011): CABG in ischemic HFrEF
- TOPCAT (2014): Spironolactone for HFpEF
- TRED-HF (2018): Withdrawal of medications in dilated cardiomyopathy
- V-HeFT (1986): ISDN/hydralazine in HFrEF
- V-HeFT II (1991): Enalapril vs. ISDN/hydralazine in HFrEF
- Val-HeFT (2001): Valsartan in HFrEF
- VALIANT (2003): Valsartan vs. captopril in MI with LV dysfunction
Heart failure
- GISSI-HF (2008): PUFA in patients with heart failure
Hemorrhage
- ANNEXA-4 (2016): Andexanet alfa for factor Xa inhibitor reversal
Hyperlipidemia
- 4S (1994): Simvastatin in stable CAD
- CORONA (2007): Rosuvastatin in ischemic HFrEF
- HPS Statin (2002): Simvastatin in high risk for CVD
- IMPROVE-IT (2015): Ezetimibe+simvastatin after ACS
- JUPITER (2008): Rosuvastatin for primary CV prevention
- MIRACL (2001): Atorvastatin in UA/NSTEMI
- ODYSSEY LONG TERM (2015): PCSK9 inhibitor alirocumab for HLD
- PROVE IT-TIMI 22 (2004): Pravastatin vs. atorvastatin after ACS
- Stopping Statins at the End of Life (2015): Palliative statin discontinuation
- TNT (2005): Atorvastatin in stable CAD
- WOSCOPS (1995): Pravastatin in CAD
Hypertension
- ACCOMPLISH (2008): Benazepril/amlodipine vs. benazepril/HCTZ in HTN
- ALLHAT (2002): Chlorthalidone in HTN
- Blood Pressure Reduction in Black Barbershops (2018): PharmD-guided BP reduction for black men in barbershops
- BPROAD (2024): Intensive BP control in DM
- CORAL (2014): Stenting vs. medical therapy in RAS
- DASH (1997): DASH diet in HTN
- HYVET (2008): Elderly HTN treatment
- PATHWAY-2 (2015): Spironolactone for resistant HTN
- SPRINT (2015): BP targets in high-risk patients
- SPYRAL HTN-ON MED (2018): Renal denervation in resistant hypertension
- STEP (2021): Intensive BP control hypertension
- TONE (1998): Na reduction and weight loss for HTN control in elderly
Iron Deficiency Anemia
- FAIR-HF (2009): Parenteral iron in HFrEF with iron deficiency
Mitral Regurgitation
Myeloproliferative Neoplasms
- CYTO-PV (2013): Hematocrit thresholds in PV
Myocardial Infarction
- ATLAS ACS-2, TIMI 51 (2012): Rivaroxaban after ACS
- AURORA (2009): Rosuvastatin in ESRD
- AVOID (2015): Supplemental oxygen in STEMI
- CAST I (1991): Antiarrhythmics post-MI
- CHAMPION PHOENIX (2013): Cangrelor during urgent or elective PCI
- CHARISMA (2006): Aspirin/clopidogrel vs. aspirin for CV prevention
- COMMIT (2005): Metoprolol in acute MI
- DanGer Shock (2024): Impella in STEMI w/cardiogenic shock
- DAPT (2014): Aspirin/clopidogrel duration after PCI
- DETO2X-AMI (2017): Oxygen for suspected MI
- DINAMIT (2004): ICD for ICM shortly after MI
- EPHESUS (2003): Eplerenone post-MI with HFrEF
- FRISC-II (1999): Early invasive strategy in UA/NSTEMI
- GISSI-3 (1994): Lisinopril in acute MI
- GUSTO (1993): tPA in ACS
- HS troponin-T to rule out MI (2014): High sensitivity troponin for acute chest pain
- IABP-SHOCK II (2012): IABP in MI and cardiogenic shock
- IMPROVE-IT (2015): Ezetimibe+simvastatin after ACS
- ISIS-2 (1988): Aspirin ± streptokinase in acute MI
- MADIT-II (2002): ICD post-MI with HFrEF
- OASIS-5 (2006): Fondaparinux vs. enoxaparin in NSTE-ACS
- OAT (2006): PCI+OMT vs. OMT 3-28 days after MI
- PEGASUS-TIMI 54 (2015): Extended ticagrelor+ASA after MI
- PIONEER AF-PCI (2016): DOAC, VKA, antiplatelets after PCI with stent
- PRAMI (2013): PCI to high-risk non-infarct arteries in STEMI
- REDUCE-AMI (2024): Beta-blockers if post-AMI LVEF ≥50%
- SAVE (1992): Captopril in MI with LV dysfunction
- SHOCK (1999): Early PCI/CABG in MI + shock
- TIMACS (2009): Early vs. delayed PCI in NSTEMI and UA
- VALIANT (2003): Valsartan vs. captopril in MI with LV dysfunction
Osteoarthritis
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
Patent Foramen Ovale
- CLOSURE I (2012): PFO closure in cryptogenic stroke
- RESPECT (2013): PFO closure in cryptogenic stroke
Pericarditis
- AIRTRIP (2016): Anakinra in colchicine-resistant pericarditis
- ICAP (2013): Colchicine in the first episode of acute pericarditis
Peripheral Artery Disease
- VOYAGER-PAD (2020): Rivaroxaban 2.5mg BID in PAD
Peripheral Vascular Disease
- EUCLID (Ticagrelor) (2017): Ticagrelor vs. clopidogrel in symptomatic PAD
- HPS2-THRIVE (2014): Niacin in atherosclerotic disease
Polycythemia Vera
- CYTO-PV (2013): Hematocrit thresholds in PV
Pulmonary Embolism
- MARINER (2017): Rivaroxaban VTE ppx after medical admission
- MOPETT (2013): Low-dose tPA for submassive PE
Respiratory Failure
- DONATE-HCV (2019): Donor HCV positive heart and lung transplant
Rheumatoid Arthritis
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
Shock
- IABP-SHOCK II (2012): IABP in MI and cardiogenic shock
- SHOCK (1999): Early PCI/CABG in MI + shock
Stroke
- ACCORD Lipid (2010): Fibrate add-on to statins in T2DM
- ACTIVE A (2009): ASA/clopidogrel vs. ASA in AF
- ACTIVE W (2006): ASA/clopidogrel vs. warfarin in AF
- ARISTOTLE (2011): Apixaban vs. warfarin in AF
- AURORA (2009): Rosuvastatin in ESRD
- AVERROES (2011): Apixaban vs. ASA in AF
- BRIDGE (2015): LMWH bridging for surgery in AF
- CAPRIE (1996): Clopidogrel vs. aspirin in CV disease
- CHARISMA (2006): Aspirin/clopidogrel vs. aspirin for CV prevention
- CLOSURE I (2012): PFO closure in cryptogenic stroke
- CREST (2010): Stenting vs. CEA in carotid stenosis
- DAPT (2014): Aspirin/clopidogrel duration after PCI
- EMBRACE (2014): Extended EKG monitoring after cryptogenic stroke
- HOPE (2000): Ramipril in patients with high CV risk
- JUPITER (2008): Rosuvastatin for primary CV prevention
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
- ORBIT-AF (2013): ASA/warfarin vs. warfarin in AF
- ORIGIN n-3 Fatty Acids (2012): Fish oil for high-risk CVD
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
- PREDIMED (2013): Mediterranean diet in CVD prevention
- PROTECT AF (2009): LAA closure vs. warfarin in AF
- RE-LY (2009): Dabigatran vs. warfarin in AF
- RESPECT (2013): PFO closure in cryptogenic stroke
- ROCKET AF (2011): Rivaroxaban vs. warfarin in AF
- SPAF (1991): Aspirin and warfarin in AF
- WASID (2005): Warfarin vs. aspirin for intracranial atherosclerosis
Sudden Cardiac Death
- VEST (2018): Wearable cardioverter-defibrillator post-MI
Transient Ischemic Attack
- ACTIVE A (2009): ASA/clopidogrel vs. ASA in AF
- ACTIVE W (2006): ASA/clopidogrel vs. warfarin in AF
- ARISTOTLE (2011): Apixaban vs. warfarin in AF
- AVERROES (2011): Apixaban vs. ASA in AF
- CAPRIE (1996): Clopidogrel vs. aspirin in CV disease
- CLOSURE I (2012): PFO closure in cryptogenic stroke
- CREST (2010): Stenting vs. CEA in carotid stenosis
- HOPE (2000): Ramipril in patients with high CV risk
- JUPITER (2008): Rosuvastatin for primary CV prevention
- PREDIMED (2013): Mediterranean diet in CVD prevention
- RE-LY (2009): Dabigatran vs. warfarin in AF
- RESPECT (2013): PFO closure in cryptogenic stroke
- ROCKET AF (2011): Rivaroxaban vs. warfarin in AF
Type 2 Diabetes
- BPROAD (2024): Intensive BP control in DM
Unstable Arrhythmia
- PRAETORIAN (2020): Transvenous vs. subq ICD to prevent sudden cardiac death
Valvular Disease
- RE-ALIGN (2013): Dabigatran in mechanical heart valves
Venous Thromboembolism
- MARINER (2017): Rivaroxaban VTE ppx after medical admission
- MOPETT (2013): Low-dose tPA for submassive PE
Ventricular Tachycardia
- DANISH (2016): ICD vs. standard care in NICM and LVEF ≤35%
- MUSTT (1999): ICD and antiarrhythmics in mild HFrEF and NSVT
- VANISH (2016): Ablation vs. antiarrhythmic drugs in VT
Critical Care
Acetaminophen Overdose
- NACSTOP (2019): 12 vs. 20 hours of NAC in APAP overdose
Acute Coronary Syndrome
- IABP-SHOCK II (2012): IABP in MI and cardiogenic shock
- SHOCK (1999): Early PCI/CABG in MI + shock
Acute Kidney Injury
- AKIKI (2016): Early vs. late RRT in severe AKI in ICU
- ATN (2008): RRT intensity in ATN
- IDEAL-ICU (2018): Early vs. delayed RRT in septic shock
- SALT-ED (2018): Balanced crystalloids vs. NS in non-critical ED patients
Acute Respiratory Distress Syndrome
- ACURASYS (2010): Cisatracurium in ARDS
- ARDSNet (2000): Low vs. traditional volumes in ARDS
- FACTT (2006): Fluid management in ARDS
- OSCILLATE (2013): High-frequency oscillatory vent in early ARDS
- PROSEVA (2013): Prone ventilation in ARDS
- ROSE (2019): Cisatracurium NM blockade in ARDS
Anemia
- IRONMAN (2016): IV iron in critical illness
- TRICC (1999): Transfusion thresholds in ICU
- TRISS (2014): Transfusion thresholds in sepsis
Cardiac Arrest
- HACA (2002): Hypothermia for cardiac arrest
- TTM (2014): 33 vs. 36°C body temperature after cardiac arrest
- TTM2 (2021): 33°C vs. normothermia after cardiac arrest
Catheter-Related Bloodstream Infection
- 3SITES (2015): Central line complications by insertion site
Critical Illness
- 3SITES (2015): Central line complications by insertion site
- ATN (2008): RRT intensity in ATN
- BICAR-ICU (2018): Bicarbonate in severe metabolic acidosis
- CALORIES (2014): Early parenteral vs. enteral feeds in ICU
- IRONMAN (2016): IV iron in critical illness
- MIND-USA (2018): Antipsychotics in ICU delirium
- PRORATA (2010): Procalcitonin-guided antibiotics
- SAFE (2004): Albumin vs. saline in ICU
- SEDCOM (2009): Dexmedetomidine vs. midazolam for sedation
- SMART-MED and SMART-SURG (2018): NS vs. balanced crystalloids in ICU
- Yang-Tobin Study (1991): RSBI for predicting weaning
Delirium
- AID-ICU (2022): Haloperidol for ICU delirium
- MIND-USA (2018): Antipsychotics in ICU delirium
- SPICE III (2019): Dexmedetomidine in ICU sedation
Diabetes Mellitus
- RABBIT 2 (2007): Basal-bolus insulin in inpatients with DM
Fever
- HEAT (2015): Acetaminophen in febrile ICU patients
Gastrointestinal Hemorrhage
- GI bleeding in ICU patients (1994): Risk factors for GI bleeds in ICU patients
Heart Failure
- ADVOR (2022): Acetazolamide vs. placebo in acute HF
- ESCAPE (2005): PA catheters in acute HF management
Hemorrhage
- PROPPR (2015): Transfusion ratios in hemorrhagic shock
Hypotension
- 65 Trial (2020): MAP 60-65 vs. usual care in vasodilatory hypotension in ICU
Hypovolemia
- SALT-ED (2018): Balanced crystalloids vs. NS in non-critical ED patients
Infection
- ACORN (2023): Empiric cefepime vs. pip-tazo for infection
Metabolic Acidosis
- BICAR-ICU (2018): Bicarbonate in severe metabolic acidosis
Myocardial Infarction
- IABP-SHOCK II (2012): IABP in MI and cardiogenic shock
- SHOCK (1999): Early PCI/CABG in MI + shock
Pneumonia
Pulmonary Embolism
Respiratory Failure
- Daily ICU Sedation Holidays (2000): Scheduled daily sedation holidays in intubated patients
Sedation
- SPICE III (2019): Dexmedetomidine in ICU sedation
Sepsis
- ADRENAL (2018): Hydrocortisone in septic shock
- ALBIOS (2014): Daily albumin in severe sepsis
- Annane Trial (2002): Corticosteroids in septic shock
- APROCCHSS (2018): Steroids in septic shock
- ARISE (2014): EGDT vs. usual care in sepsis
- CORTICUS (2008): Hydrocortisone in septic shock
- HEAT (2015): Acetaminophen in febrile ICU patients
- Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock (2017): Hydrocortisone, Vit C, and thiamine in sepsis
- HYPRESS (2016): Hydrocortisone in severe sepsis
- ProCESS (2014): EGDT in septic shock
- ProMISe (2015): Multicenter EGDT trial in severe sepsis
- PROWESS (2001): Activated protein C in severe sepsis
- PROWESS-SHOCK (2012): Activated protein C in septic shock
- Rivers Trial (2001): Early goal-directed therapy in sepsis
- SEPSISPAM (2014): MAP 65-70 vs. 80-85 mmHg in sepsis
- SOAP II (2010): Dopamine vs. norepinephrine in shock
- TRISS (2014): Transfusion thresholds in sepsis
- VASST (2008): Vasopressin in septic shock
Septic Shock
- IDEAL-ICU (2018): Early vs. delayed RRT in septic shock
- LOVIT (2022): Vitamin C in sepsis
- VITAMINS (2020): Vitamin C, hydrocortisone, & thiamine in septic shock
Shock
- ADRENAL (2018): Hydrocortisone in septic shock
- Annane Trial (2002): Corticosteroids in septic shock
- ATHOS-3 (2017): Angiotensin II vs. placebo in vasodilatory shock
- CORTICUS (2008): Hydrocortisone in septic shock
- CRISTAL (2013): Colloids vs. crystalloids in shock
- FEAST (2011): Fluid resuscitation in Sub-Saharan Africa
- Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock (2017): Hydrocortisone, Vit C, and thiamine in sepsis
- IABP-SHOCK II (2012): IABP in MI and cardiogenic shock
- ProMISe (2015): Multicenter EGDT trial in severe sepsis
- PROPPR (2015): Transfusion ratios in hemorrhagic shock
- PROWESS (2001): Activated protein C in severe sepsis
- PROWESS-SHOCK (2012): Activated protein C in septic shock
- Rivers Trial (2001): Early goal-directed therapy in sepsis
- SEPSISPAM (2014): MAP 65-70 vs. 80-85 mmHg in sepsis
- SHOCK (1999): Early PCI/CABG in MI + shock
- SOAP II (2010): Dopamine vs. norepinephrine in shock
- TRISS (2014): Transfusion thresholds in sepsis
- VASST (2008): Vasopressin in septic shock
Stress Hyperglycemia
- Leuven Surgical Trial (2001): Intensive glycemic therapy in the surgical ICU
- NICE-SUGAR (2009): Intensive glycemic therapy in ICU
Stress Ulcer
- POP-UP (2016): PPIs for stress ulcer prophylaxis
Stress Ulcer Prophylaxis
- SUP-ICU (2018): Routine PPI use in the ICU
Stroke
- NINDS (1995): tPA in ischemic stroke
Trauma
- PROPPR (2015): Transfusion ratios in hemorrhagic shock
Venous Thromboembolism
Critical Care Medicine
Hypoxemic Respiratory Failure
- FLORALI (2015): High-flow oxygen in respiratory failure
Dermatology
Warts
- Duct Tape for Treatment of the Common Wart (2002): Duct tape vs. cryotherapy for warts
Emergency Medicine
Acetaminophen Overdose
- NACSTOP (2019): 12 vs. 20 hours of NAC in APAP overdose
Acute Coronary Syndrome
- HS troponin-T to rule out MI (2014): High sensitivity troponin for acute chest pain
Acute Respiratory Infection
- MITIGATE (2019): Antibiotic stewardship in respiratory infections
Cardiac Arrest
- TTM2 (2021): 33°C vs. normothermia after cardiac arrest
Chronic Pain
- SPACE (2018): Opioids vs. non-opioids in chronic MSK pain
Epistaxis
- TXA for Epistaxis Associated with Antiplatelet Agents (2018): TXA vs. packing for antiplatelet agent-related epistaxis
Heart Failure
- ADVOR (2022): Acetazolamide vs. placebo in acute HF
Hemorrhage
- ANNEXA-4 (2016): Andexanet alfa for factor Xa inhibitor reversal
- PROPPR (2015): Transfusion ratios in hemorrhagic shock
Infection
- ACORN (2023): Empiric cefepime vs. pip-tazo for infection
Myocardial Infarction
- HS troponin-T to rule out MI (2014): High sensitivity troponin for acute chest pain
Pulmonary Embolism
- ADJUST-PE (2014): Age-adjusted D-dimer for PE
- PERC (2008): PE rule-out criteria
- PROPER (2018): Validation of PERC score in PE
Sepsis
- ProMISe (2015): Multicenter EGDT trial in severe sepsis
- Rivers Trial (2001): Early goal-directed therapy in sepsis
- SOAP II (2010): Dopamine vs. norepinephrine in shock
Shock
- ProMISe (2015): Multicenter EGDT trial in severe sepsis
- PROPPR (2015): Transfusion ratios in hemorrhagic shock
- Rivers Trial (2001): Early goal-directed therapy in sepsis
- SOAP II (2010): Dopamine vs. norepinephrine in shock
Status Epilepticus
- EcLiPSE (2019): Levetiracetam vs. phenytoin in status epilepticus
Trauma
- Canadian CT Head Rule (2001): CT head rules for trauma
- CRASH-2 (2010): Tranexamic acid in trauma
- PROPPR (2015): Transfusion ratios in hemorrhagic shock
Urinary Tract Infection
- AIDA-WP2 (2018): Nitrofurantoin vs. fosfomycin in UTI
Venous Thromboembolism
- ADJUST-PE (2014): Age-adjusted D-dimer for PE
Endocrinology
Anemia
- TREAT (2009): Darbepoetin in CKD and T2DM
Cardiovascular Disease
- LEADER (2016): Liraglutide and CVD endpoints in T2DM
- Look AHEAD (2013): Weight loss and exercise in T2DM
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
- SUSTAIN-6 (2016): GLP-1 in DM if high CVD risk
Chronic Kidney Disease
- FIDELIO-DKD (2020): Mineralocorticoid antagonist in CKD/T2DM
- RENAAL (2001): ARBs in diabetic nephropathy
- TREAT (2009): Darbepoetin in CKD and T2DM
Coronary Artery Disease
- ACCORD Lipid (2010): Fibrate add-on to statins in T2DM
- BARI 2D (2009): CABG/PCI vs. OMT in diabetes with CAD
- FREEDOM (2012): CABG vs. PCI for CAD in T2DM
- WHI (2002): Postmenopausal estrogen/progesterone
Diabetes Mellitus
- ACCORD (2008): Intensive glycemic therapy in T2DM
- ACCORD BP (2010): Intensive BP control in T2DM
- ACCORD Lipid (2010): Fibrate add-on to statins in T2DM
- ADVANCE (2008): Intensive glycemic therapy in T2DM
- BARI 2D (2009): CABG/PCI vs. OMT in diabetes with CAD
- CANVAS (2017): Canagliflozin for CV outcomes in T2DM
- CREDENCE (2019): Canagliflozin in diabetic nephropathy
- CSG Captopril Trial (1993): Captopril in T1DM nephropathy
- DCCT (1993): Intensive glycemic therapy in T1DM
- DPP (2002): Metformin and intensive lifestyle in prediabetes
- EDIC (2005): Intensive glycemic therapy in T1DM
- EMPA-REG OUTCOME (2015): Empagliflozin for CV outcomes in T2DM
- FIDELIO-DKD (2020): Mineralocorticoid antagonist in CKD/T2DM
- FREEDOM (2012): CABG vs. PCI for CAD in T2DM
- IDNT (2001): ARBs in diabetic nephropathy
- LEADER (2016): Liraglutide and CVD endpoints in T2DM
- Look AHEAD (2013): Weight loss and exercise in T2DM
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
- RABBIT 2 (2007): Basal-bolus insulin in inpatients with DM
- RENAAL (2001): ARBs in diabetic nephropathy
- STAMPEDE (2012): Gastric bypass vs. medical therapy for T2DM
- STOP-NIDDM (2002): Acarbose to prevent diabetes in high-risk patients
- SUSTAIN-6 (2016): GLP-1 in DM if high CVD risk
- TREAT (2009): Darbepoetin in CKD and T2DM
- UKPDS 33 (1998): Intensive glycemic therapy in T2DM
- UKPDS 34 (1998): Metformin in T2DM
- VA-NEPHRON D (2013): ACE+ARB in DM nephropathy
- VADT (2009): Intensive glycemic therapy in T2DM
Diabetic Nephropathy
- CREDENCE (2019): Canagliflozin in diabetic nephropathy
- CSG Captopril Trial (1993): Captopril in T1DM nephropathy
- IDNT (2001): ARBs in diabetic nephropathy
- VA-NEPHRON D (2013): ACE+ARB in DM nephropathy
Heart Failure
- DAPA-HF (2019): Dapagliflozin in HFrEF
Hypertension
Menopause
- WHI (2002): Postmenopausal estrogen/progesterone
Obesity
- STAMPEDE (2012): Gastric bypass vs. medical therapy for T2DM
- STEP 1 (2021): Semaglutide in obesity without diabetes
Osteoporosis
- HORIZON-PFT (2007): Zoledronate vs. placebo in osteoporosis
Overweight
- STEP 1 (2021): Semaglutide in obesity without diabetes
Prediabetes
- DPP (2002): Metformin and intensive lifestyle in prediabetes
Sepsis
- CORTICUS (2008): Hydrocortisone in septic shock
Shock
- CORTICUS (2008): Hydrocortisone in septic shock
Stress Hyperglycemia
- Leuven Surgical Trial (2001): Intensive glycemic therapy in the surgical ICU
- NICE-SUGAR (2009): Intensive glycemic therapy in ICU
Stroke
- ACCORD Lipid (2010): Fibrate add-on to statins in T2DM
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
Type 2 Diabetes
- BPROAD (2024): Intensive BP control in DM
Gastroenterology
Alcoholic Hepatitis
- Pentoxifylline in Severe Alcoholic Hepatitis (2000): Pentoxifylline in alcoholic hepatitis
- Prednisolone in Severe Alcoholic Hepatitis (1992): Prednisolone vs. placebo in alcoholic hepatitis
- STOPAH (2015): Prednisolone vs. pentoxifylline in alcoholic hepatitis
Cirrhosis
- Albumin for SBP (1999): Albumin for SBP in cirrhosis
- Antibiotics in Cirrhosis with Hemorrhage (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed
- Early TIPS (2010): Early TIPS in high-risk cirrhotic variceal bleeding
Clostridium difficile
- Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile (2013): Fecal transplant in C. difficile
- Fidaxomicin in C. difficile Diarrhea (2011): Fidaxomicin in C. difficile
- MODIFY I and II (2017): Bezlotoxumab for C. diff recurrence prevention
- PLACIDE (2013): Probiotics to prevent CDAD
- Vancomycin vs. Metronidazole in C. difficile Diarrhea (2007): Vancomycin vs. metronidazole in C. difficile
Colorectal Cancer
- COLONPREV (2012): FIT vs. colonoscopy for colon cancer screening
Crohn Disease
- SONIC (2010): Infliximab ± azathioprine induction in Crohn disease
Gastrointestinal Hemorrhage
- Antibiotics in Cirrhosis with Hemorrhage (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed
- Early TIPS (2010): Early TIPS in high-risk cirrhotic variceal bleeding
- GI bleeding in ICU patients (1994): Risk factors for GI bleeds in ICU patients
- Omeprazole in Peptic Ulcer Bleeding (2000): IV PPI for GI bleeds
- Transfusion Strategies for Acute Upper Gastrointestinal Bleeding (2013): Transfusion thresholds in UGIB
Hemorrhage
- Transfusion Strategies for Acute Upper Gastrointestinal Bleeding (2013): Transfusion thresholds in UGIB
Hepatic Encephalopathy
- Rifaximin and Lactulose for HE (2013): Rifaximin/lactulose vs. lactulose for acute HE
Hepatitis C
- VALENCE (2014): Sofosbuvir+ribavirin for HCV genotypes 2 or 3
Inflammatory Bowel Disease
- SONIC (2010): Infliximab ± azathioprine induction in Crohn disease
Pancreatitis
- PANTER (2010): Step-up approach to pancreatitis
Spontaneous Bacterial Peritonitis
- Albumin for SBP (1999): Albumin for SBP in cirrhosis
Geriatrics
Bacteriuria
- Cranberry for prevention of pyuria and bacteriuria (2016): Cranberry in for prevention of pyuria and bacteriuria
Delirium
- DELIRIA-J (2014): Ramelteon vs. placebo to prevent delirium
Hypertension
- HYVET (2008): Elderly HTN treatment
Hypotension
- 65 Trial (2020): MAP 60-65 vs. usual care in vasodilatory hypotension in ICU
Pyuria
- Cranberry for prevention of pyuria and bacteriuria (2016): Cranberry in for prevention of pyuria and bacteriuria
Gynecology
Coronary Artery Disease
- WHI (2002): Postmenopausal estrogen/progesterone
Menopause
- WHI (2002): Postmenopausal estrogen/progesterone
Unplanned Pregnancy
- CHOICE (2014): Free long-acting reversible contraception in teens
Urinary Tract Infections
- S-HYDRACYST (2018): Water intake to prevent UTI
Hematology
Aggressive B-cell lymphoma
- BELINDA (2022): Tisa-cel vs. ASCT in R/R DLBCL
Anemia
- CHOIR (2006): EPO in CKD with anemia
- FOCUS (2011): Transfusion thresholds after hip surgery
- IRONMAN (2016): IV iron in critical illness
- RED-HF (2013): Darbepoetin in HFrEF
- TREAT (2009): Darbepoetin in CKD and T2DM
- TRICC (1999): Transfusion thresholds in ICU
- TRICS III (2017): Transfusion thresholds for cardiac surgery
- TRISS (2014): Transfusion thresholds in sepsis
Antiphospholipid Syndrome
- TRAPS (2018): Rivaroxaban in high-risk APLS
Atrial Fibrillation
- BRIDGE (2015): LMWH bridging for surgery in AF
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
- Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia (2019): Ibrutinib-rituximab vs. FCR in untreated CLL
Chronic Myeloid Leukemia
- IRIS (2003): Imatinib vs. IFNα/cytarabine in CML
Coronary Artery Disease
- MASTER DAPT (2021): Abbreviated DAPT in high-risk bleeding
- WOEST (2013): Clopidogrel ± ASA after PCI if on OAC
Critical Illness
- IRONMAN (2016): IV iron in critical illness
Deep Vein Thrombosis
- AMPLIFY (2013): Apixaban vs. warfarin in VTE
- AMPLIFY-EXT (2013): Apixaban after VTE treatment
- APEX (2017): Betrixaban for extended VTE prophylaxis
- ATTRACT (2017): Pharmacomechanical therapy vs. anticoagulation in DVT
- AVERT (2018): Apixaban for VTE prevention in cancer
- CARAVAGGIO (2020): Apixaban vs. dalteparin in cancer VTE
- CASSINI (2019): Rivaroxaban for VTE prevention in cancer
- CLOT (2003): LMWH vs. warfarin in cancer VTE
- DODS (2019): D-dimer based anticoagulation discontinuation
- EINSTEIN CHOICE (2017): Rivaroxaban after VTE treatment
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
- Hokusai-VTE (2018): Edoxaban vs. LMWH in cancer VTE
- MAGELLAN (2013): Rivaroxaban vs. LMWH for VTE prophylaxis
- MARINER (2017): Rivaroxaban VTE ppx after medical admission
- PREPIC (1998): IVC filters for proximal DVT
- PROLONG (2006): D-Dimer testing after VTE
- RE-COVER (2009): Dabigatran vs. warfarin in VTE
- SELECT-D (2018): Rivaroxaban vs. LMWH in cancer VTE
- SOME (2015): Occult cancer screening in unprovoked VTE
- WARFASA (2012): Aspirin after VTE treatment
Diabetes Mellitus
- TREAT (2009): Darbepoetin in CKD and T2DM
Febrile Neutropenia
- How Long (2017): Duration of empiric antibiotics in ↑risk neutropenic fever
Heart Failure
Hemorrhage
- ANNEXA (2015): Andexanet for reversing Xa inhibitors
- ANNEXA-4 (2016): Andexanet alfa for factor Xa inhibitor reversal
- PROPPR (2015): Transfusion ratios in hemorrhagic shock
- RE-VERSE AD (2015): Idarucizumab for dabigatran reversal
Hip Fracture
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
- FOCUS (2011): Transfusion thresholds after hip surgery
Iron Deficiency Anemia
- FAIR-HF (2009): Parenteral iron in HFrEF with iron deficiency
Leukemia
- Lo-Coco 2013 (2013): ATRA-ATO vs. ATRA-chemotherapy in APL
Lymphoma
- BELINDA (2022): Tisa-cel vs. ASCT in R/R DLBCL
- Ibrutinib in Waldenstrom macroglobulinemia (2015): Second-line ibrutinib in WM
- StiL (2013): BR vs. R-CHOP for indolent lymphomas
Meniscal Tear
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
Multiple Myeloma
- CRB-401 (2019): Ide-cel CART in myeloma
- LenDex in High-Risk Smoldering Myeloma (2013): Lenalidomide/dexamethasone in smoldering MM
Myeloproliferative Neoplasms
Osteoarthritis
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
Paroxysmal Nocturnal Hemoglobinuria
- TRIUMPH (2006): Eculizumab in PNH
Polycythemia Vera
- CYTO-PV (2013): Hematocrit thresholds in PV
Post-Thrombotic Syndrome
- ATTRACT (2017): Pharmacomechanical therapy vs. anticoagulation in DVT
Pregnancy
- TIPPS (2014): Dalteparin in pregnant woman with thrombophilias
Pulmonary Embolism
- ADJUST-PE (2014): Age-adjusted D-dimer for PE
- AMPLIFY (2013): Apixaban vs. warfarin in VTE
- AMPLIFY-EXT (2013): Apixaban after VTE treatment
- APEX (2017): Betrixaban for extended VTE prophylaxis
- AVERT (2018): Apixaban for VTE prevention in cancer
- CARAVAGGIO (2020): Apixaban vs. dalteparin in cancer VTE
- CASSINI (2019): Rivaroxaban for VTE prevention in cancer
- CLOT (2003): LMWH vs. warfarin in cancer VTE
- DODS (2019): D-dimer based anticoagulation discontinuation
- EINSTEIN CHOICE (2017): Rivaroxaban after VTE treatment
- EINSTEIN-PE (2012): Rivaroxaban vs. warfarin in PE
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
- Hokusai-VTE (2018): Edoxaban vs. LMWH in cancer VTE
- MAGELLAN (2013): Rivaroxaban vs. LMWH for VTE prophylaxis
- MARINER (2017): Rivaroxaban VTE ppx after medical admission
- PEITHO (2014): tPA for submassive PE
- PERC (2008): PE rule-out criteria
- PESIT (2016): Prevalence of PE in syncope
- PIOPED II (2006): Accuracy of CT for PE
- PREPIC (1998): IVC filters for proximal DVT
- PROLONG (2006): D-Dimer testing after VTE
- RE-COVER (2009): Dabigatran vs. warfarin in VTE
- SELECT-D (2018): Rivaroxaban vs. LMWH in cancer VTE
- SOME (2015): Occult cancer screening in unprovoked VTE
- WARFASA (2012): Aspirin after VTE treatment
Sepsis
- TRISS (2014): Transfusion thresholds in sepsis
Shock
- PROPPR (2015): Transfusion ratios in hemorrhagic shock
- TRISS (2014): Transfusion thresholds in sepsis
Sickle Cell Disease
- HOPE (Sickle Cell Disease) (2019): Voxelotor in sickle cell disease
- MSH (1995): Hydroxyurea in sickle-cell disease
- SUSTAIN (2017): Crizanlizumab vs. placebo in SCD
Small Lymphocytic Lymphoma
- Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia (2019): Ibrutinib-rituximab vs. FCR in untreated CLL
Stroke
- BRIDGE (2015): LMWH bridging for surgery in AF
Syncope
- PESIT (2016): Prevalence of PE in syncope
Thrombocytopenia
- TOPPS (2013): Platelet transfusions in blood cancers
Thrombophilia
- TIPPS (2014): Dalteparin in pregnant woman with thrombophilias
Trauma
Valvular Disease
- RE-ALIGN (2013): Dabigatran in mechanical heart valves
Venous Thromboembolism
- ADJUST-PE (2014): Age-adjusted D-dimer for PE
- AMPLIFY (2013): Apixaban vs. warfarin in VTE
- AMPLIFY-EXT (2013): Apixaban after VTE treatment
- APEX (2017): Betrixaban for extended VTE prophylaxis
- ASPIRE (2012): Aspirin after VTE treatment
- ATTRACT (2017): Pharmacomechanical therapy vs. anticoagulation in DVT
- AVERT (2018): Apixaban for VTE prevention in cancer
- CARAVAGGIO (2020): Apixaban vs. dalteparin in cancer VTE
- CASSINI (2019): Rivaroxaban for VTE prevention in cancer
- CLOT (2003): LMWH vs. warfarin in cancer VTE
- DODS (2019): D-dimer based anticoagulation discontinuation
- EINSTEIN CHOICE (2017): Rivaroxaban after VTE treatment
- EINSTEIN-PE (2012): Rivaroxaban vs. warfarin in PE
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
- Hokusai-VTE (2018): Edoxaban vs. LMWH in cancer VTE
- MAGELLAN (2013): Rivaroxaban vs. LMWH for VTE prophylaxis
- MARINER (2017): Rivaroxaban VTE ppx after medical admission
- PEITHO (2014): tPA for submassive PE
- PESIT (2016): Prevalence of PE in syncope
- PIOPED II (2006): Accuracy of CT for PE
- PREPIC (1998): IVC filters for proximal DVT
- PREPIC 2 (2015): IVC filters for high-risk PE
- PROLONG (2006): D-Dimer testing after VTE
- RE-COVER (2009): Dabigatran vs. warfarin in VTE
- SELECT-D (2018): Rivaroxaban vs. LMWH in cancer VTE
- SOME (2015): Occult cancer screening in unprovoked VTE
- TIPPS (2014): Dalteparin in pregnant woman with thrombophilias
- WARFASA (2012): Aspirin after VTE treatment
Waldenström Macroglobulinemia
- ASPEN (2020): Zanubrutinib vs. ibrutinib in WM
- Ibrutinib in Waldenstrom macroglobulinemia (2015): Second-line ibrutinib in WM
Infectious Disease
Acute Respiratory Infection
- MITIGATE (2019): Antibiotic stewardship in respiratory infections
Appendicitis
- APPAC (2015): Antibiotics vs. surgery for acute appendicitis
Bacteremia
- ARREST (2017): Rifampin in S. aureus bacteremia
Bacteriuria
- Cranberry for prevention of pyuria and bacteriuria (2016): Cranberry in for prevention of pyuria and bacteriuria
Catheter-Related Bloodstream Infection
- 3SITES (2015): Central line complications by insertion site
Cirrhosis
- Albumin for SBP (1999): Albumin for SBP in cirrhosis
- Antibiotics in Cirrhosis with Hemorrhage (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed
Clostridium difficile
- Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile (2013): Fecal transplant in C. difficile
- Fidaxomicin in C. difficile Diarrhea (2011): Fidaxomicin in C. difficile
- MODIFY I and II (2017): Bezlotoxumab for C. diff recurrence prevention
- PLACIDE (2013): Probiotics to prevent CDAD
- Vancomycin vs. Metronidazole in C. difficile Diarrhea (2007): Vancomycin vs. metronidazole in C. difficile
Covid-19
- ACTT-1 (2020): Remdesivir vs. placebo in Covid-19
- RECOVERY (Covid-19) (2020): Dexamethasone vs. usual care in Covid-19
Critical Illness
- 3SITES (2015): Central line complications by insertion site
- PRORATA (2010): Procalcitonin-guided antibiotics
ESBL Bacteremia
- MERINO (2018): Piperacillin-tazobactam for ESBL bacteremia
Endocarditis
- EASE (2012): Early surgery in endocarditis
- POET (2019): PO abx after 10d IV abx for left-sided endocarditis
Febrile Neutropenia
- How Long (2017): Duration of empiric antibiotics in ↑risk neutropenic fever
Fever
- HEAT (2015): Acetaminophen in febrile ICU patients
Gastrointestinal Hemorrhage
- Antibiotics in Cirrhosis with Hemorrhage (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed
HIV
- ANRS IPERGAY (2015): Pre-exposure prophylaxis in high-risk men
- AZT Trial (1987): Zidovudine in HIV/AIDS
- HPTN 052 (2011): Early ART in HIV
- INSIGHT START (2015): Early vs. delayed ART in HIV
- IPrEx (2010): ART in primary HIV prevention
- NA-ACCORD (2009): Early vs. delayed ART in HIV
Hepatitis C
- VALENCE (2014): Sofosbuvir+ribavirin for HCV genotypes 2 or 3
Infection
- ACORN (2023): Empiric cefepime vs. pip-tazo for infection
Intraabdominal Infection
- STOP-IT (2015): Duration of abx in intraabdominal infection
Meningitis
- European Dexamethasone Study (2002): Dexamethasone in meningitis
Osteomyelitis
- OVIVA (2019): PO vs. IV antibiotics for bone/joint infection
Penicillin Allergy
- PALACE (2023): Penicillin allergy rule-out
Pleural Infection
- MIST2 (2011): tPA and/or DNase for pleural infection
Pneumonia
- 3C (2017): Antibiotic strategies in lower respiratory tract infections
- CAP-START (2015): Antibiotic strategies for PNA
- PneumA (2003): 8 vs. 15 days of antibiotics in VAP
Pyuria
- Cranberry for prevention of pyuria and bacteriuria (2016): Cranberry in for prevention of pyuria and bacteriuria
Sepsis
- HEAT (2015): Acetaminophen in febrile ICU patients
- Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock (2017): Hydrocortisone, Vit C, and thiamine in sepsis
Septic Shock
- LOVIT (2022): Vitamin C in sepsis
Shock
- Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock (2017): Hydrocortisone, Vit C, and thiamine in sepsis
Spontaneous Bacterial Peritonitis
- Albumin for SBP (1999): Albumin for SBP in cirrhosis
Tuberculosis
- PREVENT TB (2011): Rifapentine/isoniazid in latent TB
Urinary Tract Infection
- AIDA-WP2 (2018): Nitrofurantoin vs. fosfomycin in UTI
Urinary Tract Infections
- S-HYDRACYST (2018): Water intake to prevent UTI
Interventional Radiology
Cirrhosis
- Early TIPS (2010): Early TIPS in high-risk cirrhotic variceal bleeding
Deep Vein Thrombosis
- PREPIC (1998): IVC filters for proximal DVT
Gastrointestinal Hemorrhage
- Early TIPS (2010): Early TIPS in high-risk cirrhotic variceal bleeding
Pulmonary Embolism
- PREPIC (1998): IVC filters for proximal DVT
Stroke
- SAMMPRIS (2011): Stenting in intracranial stenosis
Venous Thromboembolism
Nephrology
ANCA-Associated Vasculitis
- RITUXVAS (2010): Rituximab in ANCA-Renal Vasculitis
Acute Coronary Syndrome
- ACT (2011): Acetylcysteine with IV contrast
Acute Kidney Injury
- ACT (2011): Acetylcysteine with IV contrast
- AKIKI (2016): Early vs. late RRT in severe AKI in ICU
- ATN (2008): RRT intensity in ATN
- IDEAL-ICU (2018): Early vs. delayed RRT in septic shock
- SALT-ED (2018): Balanced crystalloids vs. NS in non-critical ED patients
Anemia
Cardiovascular Disease
- AURORA (2009): Rosuvastatin in ESRD
- CORAL (2014): Stenting vs. medical therapy in RAS
- EVOLVE (2012): Cinacalcet in ESRD
- LIFE (2002): ARB vs. B-blocker in HTN with LVH
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
Chronic Kidney Disease
- AASK (2002): BP management for CKD in African Americans
- Benazepril in Severe CKD (2006): Benazepril in non-diabetic CKD
- CHOIR (2006): EPO in CKD with anemia
- CORAL (2014): Stenting vs. medical therapy in RAS
- DAPA-CKD (2020): Dapagliflozin in CKD±T2DM
- EVOLVE (2012): Cinacalcet in ESRD
- FIDELIO-DKD (2020): Mineralocorticoid antagonist in CKD/T2DM
- HEMO (2002): High dialysis dose and high-flux membrane in hemodialysis
- IDEAL (2010): Early vs. late dialysis in CKD
- NCDS (1981): Dialysis prescriptions in ESRD
- RENAAL (2001): ARBs in diabetic nephropathy
- TREAT (2009): Darbepoetin in CKD and T2DM
Critical Illness
- ATN (2008): RRT intensity in ATN
- SMART-MED and SMART-SURG (2018): NS vs. balanced crystalloids in ICU
Diabetes Mellitus
- CANVAS (2017): Canagliflozin for CV outcomes in T2DM
- CREDENCE (2019): Canagliflozin in diabetic nephropathy
- CSG Captopril Trial (1993): Captopril in T1DM nephropathy
- FIDELIO-DKD (2020): Mineralocorticoid antagonist in CKD/T2DM
- IDNT (2001): ARBs in diabetic nephropathy
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
- RENAAL (2001): ARBs in diabetic nephropathy
- TREAT (2009): Darbepoetin in CKD and T2DM
- VA-NEPHRON D (2013): ACE+ARB in DM nephropathy
Diabetic Nephropathy
- CREDENCE (2019): Canagliflozin in diabetic nephropathy
- CSG Captopril Trial (1993): Captopril in T1DM nephropathy
- IDNT (2001): ARBs in diabetic nephropathy
- VA-NEPHRON D (2013): ACE+ARB in DM nephropathy
Hypertension
- AASK (2002): BP management for CKD in African Americans
- ALLHAT (2002): Chlorthalidone in HTN
- ASTRAL (2009): Revascularization in RAS
- CORAL (2014): Stenting vs. medical therapy in RAS
- DASH (1997): DASH diet in HTN
- HYVET (2008): Elderly HTN treatment
- LIFE (2002): ARB vs. B-blocker in HTN with LVH
- PATHWAY-2 (2015): Spironolactone for resistant HTN
Hypovolemia
- SALT-ED (2018): Balanced crystalloids vs. NS in non-critical ED patients
Kidney Transplant
- ELITE-Symphony (2007): Immunosuppression after kidney transplant
Lupus
- ALMS (2009): MMF vs. CTX in lupus nephritis
Lupus Nephritis
- ALMS (2009): MMF vs. CTX in lupus nephritis
Myocardial Infarction
- AURORA (2009): Rosuvastatin in ESRD
Renal Artery Stenosis
- ASTRAL (2009): Revascularization in RAS
Renal Vasculitis
- RITUXVAS (2010): Rituximab in ANCA-Renal Vasculitis
Septic Shock
- IDEAL-ICU (2018): Early vs. delayed RRT in septic shock
Stroke
- AURORA (2009): Rosuvastatin in ESRD
- LIFE (2002): ARB vs. B-blocker in HTN with LVH
- ONTARGET (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
Vasculitis
- CYCLOPS (2009): Pulse cyclophosphamide for ANCA vasculitis
- RITUXVAS (2010): Rituximab in ANCA-Renal Vasculitis
Neurology
Atrial Fibrillation
- ACTIVE A (2009): ASA/clopidogrel vs. ASA in AF
- ACTIVE W (2006): ASA/clopidogrel vs. warfarin in AF
- ARISTOTLE (2011): Apixaban vs. warfarin in AF
- AVERROES (2011): Apixaban vs. ASA in AF
- EMBRACE (2014): Extended EKG monitoring after cryptogenic stroke
- ORBIT-AF (2013): ASA/warfarin vs. warfarin in AF
- RE-LY (2009): Dabigatran vs. warfarin in AF
- ROCKET AF (2011): Rivaroxaban vs. warfarin in AF
- SPAF (1991): Aspirin and warfarin in AF
Cardiac Arrest
- HACA (2002): Hypothermia for cardiac arrest
- TTM (2014): 33 vs. 36°C body temperature after cardiac arrest
Cardiovascular Disease
- ORIGIN n-3 Fatty Acids (2012): Fish oil for high-risk CVD
Carotid Stenosis
- CREST (2010): Stenting vs. CEA in carotid stenosis
- ECST (1998): CEA in symptomatic carotid stenosis
- NASCET (1998): CEA in symptomatic carotid stenosis
Coronary Artery Disease
- CAPRIE (1996): Clopidogrel vs. aspirin in CV disease
- HOPE (2000): Ramipril in patients with high CV risk
- ORIGIN n-3 Fatty Acids (2012): Fish oil for high-risk CVD
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
Epilepsy
- RAMPART (2012): Midazolam vs. lorazepam for status epilepticus
- Veterans Affairs Status Epilepticus Cooperative Study Group (1998): Antiepileptics in status epilepticus
Hyperlipidemia
- SPARCL (2006): Atorvastatin after stroke
Hypertension
- PROGRESS (2001): Perindopril±indapamide after stroke
Hypotension
- 65 Trial (2020): MAP 60-65 vs. usual care in vasodilatory hypotension in ICU
Intracranial Hypertension
- RESCUEicp (2016): Craniectomy vs. medical care for intracranial hypertension
Meningitis
- European Dexamethasone Study (2002): Dexamethasone in meningitis
Osteoarthritis
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
Patent Foramen Ovale
- CLOSURE I (2012): PFO closure in cryptogenic stroke
- RESPECT (2013): PFO closure in cryptogenic stroke
Rheumatoid Arthritis
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
Seizure
- RAMPART (2012): Midazolam vs. lorazepam for status epilepticus
Status Epilepticus
- EcLiPSE (2019): Levetiracetam vs. phenytoin in status epilepticus
Stroke
- ACTIVE A (2009): ASA/clopidogrel vs. ASA in AF
- ACTIVE W (2006): ASA/clopidogrel vs. warfarin in AF
- ARISTOTLE (2011): Apixaban vs. warfarin in AF
- AVERROES (2011): Apixaban vs. ASA in AF
- CAPRIE (1996): Clopidogrel vs. aspirin in CV disease
- CHANCE (2013): ASA/clopidogrel vs. ASA in TIA/stroke
- CLOSURE I (2012): PFO closure in cryptogenic stroke
- CREST (2010): Stenting vs. CEA in carotid stenosis
- DAWN (2018): Thrombectomy 6-24 hours after stroke
- ECASS III (2008): Alteplase 3-4.5h after stroke
- ECST (1998): CEA in symptomatic carotid stenosis
- EMBRACE (2014): Extended EKG monitoring after cryptogenic stroke
- ESPRIT (2006): ASA+dipyridamole in secondary stroke prevention
- FLAME (Stroke) (2011): SSRI after CVA for motor recovery
- HOPE (2000): Ramipril in patients with high CV risk
- IST (1997): Aspirin in acute ischemic stroke
- MATCH (2004): ASA/clopidogrel vs. clopidogrel in stroke
- MR CLEAN (2015): IA therapy for proximal large artery strokes
- MR RESCUE (2013): Thrombectomy vs. standard care in stroke
- NASCET (1998): CEA in symptomatic carotid stenosis
- NAVIGATE ESUS (2018): Rivaroxaban vs. ASA for ESUS (stroke)
- NINDS (1995): tPA in ischemic stroke
- ORBIT-AF (2013): ASA/warfarin vs. warfarin in AF
- ORIGIN n-3 Fatty Acids (2012): Fish oil for high-risk CVD
- POINT (2018): Aspirin/clopidogrel vs. aspirin in stroke/TIA
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
- PRoFESS (2008): ASA-dipyridamole vs. clopidogrel in stroke
- PROGRESS (2001): Perindopril±indapamide after stroke
- RE-LY (2009): Dabigatran vs. warfarin in AF
- RESPECT (2013): PFO closure in cryptogenic stroke
- ROCKET AF (2011): Rivaroxaban vs. warfarin in AF
- SAMMPRIS (2011): Stenting in intracranial stenosis
- SOCRATES (2016): Ticagrelor vs. aspirin in acute stroke or TIA
- SPAF (1991): Aspirin and warfarin in AF
- SPARCL (2006): Atorvastatin after stroke
- SPS3 Clopidogrel-ASA (2012): Clopidogrel+ASA for lacunar strokes
- SPS3-BP (2013): SBP <130 vs. SBP 130-150 after lacunar strokes
- TRACE-III (2024): tPA 4.5-24h post-stroke if ideal MRI/CT
- WAKE-UP (2018): tPA if stroke >4.5h and ideal MRI
- WARSS (2001): Aspirin vs. warfarin in ischemic stroke
- WASID (2005): Warfarin vs. aspirin for intracranial atherosclerosis
Transient Ischemic Attack
- ACTIVE A (2009): ASA/clopidogrel vs. ASA in AF
- ACTIVE W (2006): ASA/clopidogrel vs. warfarin in AF
- ARISTOTLE (2011): Apixaban vs. warfarin in AF
- AVERROES (2011): Apixaban vs. ASA in AF
- CAPRIE (1996): Clopidogrel vs. aspirin in CV disease
- CHANCE (2013): ASA/clopidogrel vs. ASA in TIA/stroke
- CLOSURE I (2012): PFO closure in cryptogenic stroke
- CREST (2010): Stenting vs. CEA in carotid stenosis
- ESPRIT (2006): ASA+dipyridamole in secondary stroke prevention
- HOPE (2000): Ramipril in patients with high CV risk
- POINT (2018): Aspirin/clopidogrel vs. aspirin in stroke/TIA
- RE-LY (2009): Dabigatran vs. warfarin in AF
- RESPECT (2013): PFO closure in cryptogenic stroke
- ROCKET AF (2011): Rivaroxaban vs. warfarin in AF
- SPARCL (2006): Atorvastatin after stroke
- SPS3 Clopidogrel-ASA (2012): Clopidogrel+ASA for lacunar strokes
Trauma
- Canadian CT Head Rule (2001): CT head rules for trauma
Traumatic Brain Injury
- RESCUEicp (2016): Craniectomy vs. medical care for intracranial hypertension
Obstetrics
Neural Tube Defects
- Hungarian Prenatal Vitamin Trial (1992): Perinatal vitamins to prevent neural tube defects
Pregnancy
- TIPPS (2014): Dalteparin in pregnant woman with thrombophilias
Thrombophilia
- TIPPS (2014): Dalteparin in pregnant woman with thrombophilias
Unplanned Pregnancy
- CHOICE (2014): Free long-acting reversible contraception in teens
Venous Thromboembolism
- TIPPS (2014): Dalteparin in pregnant woman with thrombophilias
Oncology
Aggressive B-cell lymphoma
- BELINDA (2022): Tisa-cel vs. ASCT in R/R DLBCL
Breast Cancer
- ACOSOG Z0011 (2011): ALND in SLND-positive breast cancer
- Age Trial (2006): Mammograms for 40-49 year old women
- ATLAS (2013): 10y vs. 5y tamoxifen in breast cancer
- EMILIA (2012): T-DM1 in metastatic breast cancer
- HERA (2005): Trastuzumab in breast cancer
- NSABP B-32 (2010): Sentinel LN biopsy in breast cancer
- NSABP P-1 (1998): Tamoxifen in breast cancer prevention
- STAR (2006): Tamoxifen vs. raloxifene in breast cancer prevention
- Swedish Two-County Trial (2011): Mammogram screening 29y follow-up
Cancer
- VITAL (Omega-3 arm) (2019): Omega-3 FA for CV and cancer prevention
- VITAL (Vitamin D arm) (2019): Vitamin D for cancer or CVD prevention
Cardiovascular Disease
- VITAL (Omega-3 arm) (2019): Omega-3 FA for CV and cancer prevention
- VITAL (Vitamin D arm) (2019): Vitamin D for cancer or CVD prevention
Chronic Lymphocytic Leukemia
- Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia (2019): Ibrutinib-rituximab vs. FCR in untreated CLL
Chronic Myeloid Leukemia
- IRIS (2003): Imatinib vs. IFNα/cytarabine in CML
Colorectal Cancer
- COLONPREV (2012): FIT vs. colonoscopy for colon cancer screening
Deep Vein Thrombosis
- AVERT (2018): Apixaban for VTE prevention in cancer
- CARAVAGGIO (2020): Apixaban vs. dalteparin in cancer VTE
- CASSINI (2019): Rivaroxaban for VTE prevention in cancer
- CLOT (2003): LMWH vs. warfarin in cancer VTE
- Hokusai-VTE (2018): Edoxaban vs. LMWH in cancer VTE
- SELECT-D (2018): Rivaroxaban vs. LMWH in cancer VTE
- SOME (2015): Occult cancer screening in unprovoked VTE
Leukemia
- Lo-Coco 2013 (2013): ATRA-ATO vs. ATRA-chemotherapy in APL
Lung Cancer
- CheckMate-003 (2012): Nivolumab in solid tumors
- Early Palliative Care (2010): Palliative care in NSCLC
- IALT (2004): Adjuvant cisplatin in resected NSCLC
- KEYNOTE-024 (2016): Pembrolizumab vs. chemotherapy in NSCLC
- NLST (2011): CT vs. CXR in lung cancer screening
- PARAMOUNT (2013): Maintenance pemetrexed in lung cancer
- Twice-daily RT for SCLC (1999): Twice-daily RT in limited SCLC
Lymphoma
Melanoma
- BRIM-3 (2011): Vemurafenib in BRAF V600+ melanoma
- CheckMate-003 (2012): Nivolumab in solid tumors
- MSLT-1 (2014): SLNB vs. surveillance in melanoma
Multiple Myeloma
- CRB-401 (2019): Ide-cel CART in myeloma
- LenDex in High-Risk Smoldering Myeloma (2013): Lenalidomide/dexamethasone in smoldering MM
Myeloproliferative Neoplasms
- IRIS (2003): Imatinib vs. IFNα/cytarabine in CML
Pancreatic Cancer
- MPACT (2013): Gemcitabine/nab-paclitaxel in pancreatic cancer
- PRODIGE 4 ACCORD 11 (2011): FOLFIRINOX in pancreatic cancer
Prostate Cancer
- ERSPC (2009): PSA for prostate cancer screening
- PCPT (2003): Finasteride for prostate cancer prophylaxis
Pulmonary Embolism
- AVERT (2018): Apixaban for VTE prevention in cancer
- CARAVAGGIO (2020): Apixaban vs. dalteparin in cancer VTE
- CASSINI (2019): Rivaroxaban for VTE prevention in cancer
- CLOT (2003): LMWH vs. warfarin in cancer VTE
- Hokusai-VTE (2018): Edoxaban vs. LMWH in cancer VTE
- SELECT-D (2018): Rivaroxaban vs. LMWH in cancer VTE
- SOME (2015): Occult cancer screening in unprovoked VTE
Renal Cell Carcinoma
- CheckMate-003 (2012): Nivolumab in solid tumors
- SWOG 8949 (2001): Cytoreductive nephrectomy in metastatic RCC
Small Lymphocytic Lymphoma
- Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia (2019): Ibrutinib-rituximab vs. FCR in untreated CLL
Thrombocytopenia
- TOPPS (2013): Platelet transfusions in blood cancers
Venous Thromboembolism
- AVERT (2018): Apixaban for VTE prevention in cancer
- CARAVAGGIO (2020): Apixaban vs. dalteparin in cancer VTE
- CASSINI (2019): Rivaroxaban for VTE prevention in cancer
- CLOT (2003): LMWH vs. warfarin in cancer VTE
- Hokusai-VTE (2018): Edoxaban vs. LMWH in cancer VTE
- SELECT-D (2018): Rivaroxaban vs. LMWH in cancer VTE
- SOME (2015): Occult cancer screening in unprovoked VTE
Waldenström Macroglobulinemia
- ASPEN (2020): Zanubrutinib vs. ibrutinib in WM
Ophthalmology
Macular Degeneration
- CATT (2011): Ranibizumab vs. bevacizumab for macular degeneration
Orthopedics
Deep Vein Thrombosis
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
Hip Fracture
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
Meniscal Tear
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
Osteoarthritis
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
Pulmonary Embolism
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
Venous Thromboembolism
- EPCAT II (2018): Aspirin vs. rivaroxaban for postoperative VTE prophylaxis
Pain Medicine
Chronic Pain
- SPACE (2018): Opioids vs. non-opioids in chronic MSK pain
Spinal Stenosis
- LESS (2014): Epidural steroids in spinal stenosis
Palliative Care
Hyperlipidemia
- Stopping Statins at the End of Life (2015): Palliative statin discontinuation
Lung Cancer
- Early Palliative Care (2010): Palliative care in NSCLC
Pediatrics
Asthma
- EXTRA (2011): Omalizumab in severe allergic asthma
Shock
- FEAST (2011): Fluid resuscitation in Sub-Saharan Africa
Status Epilepticus
- EcLiPSE (2019): Levetiracetam vs. phenytoin in status epilepticus
Warts
- Duct Tape for Treatment of the Common Wart (2002): Duct tape vs. cryotherapy for warts
Physical Medicine and Rehabilitation
Low back pain
- Radiograph vs. MRI for low back pain (2003): Radiograph vs. MRI for low back pain
Meniscal Tear
- METEOR (2013): Surgery vs. PT in OA with meniscal tear
Osteoarthritis
- METEOR (2013): Surgery vs. PT in OA with meniscal tear
- Moseley Trial (2002): Arthroscopy in knee OA
Spinal Stenosis
- LESS (2014): Epidural steroids in spinal stenosis
Preventive Medicine
Abdominal Aortic Aneurysm
- MASS (2009): US screening for AAA in men
Atherosclerotic Coronary Artery Disease
- ASPREE (2018): Aspirin for ASCVD 1° prevention if age >70
Breast Cancer
- Age Trial (2006): Mammograms for 40-49 year old women
- NSABP P-1 (1998): Tamoxifen in breast cancer prevention
- Swedish Two-County Trial (2011): Mammogram screening 29y follow-up
Cardiac Risk Assessment
- CARP (2004): Preop coronary revascularization if stable CAD
Clostridium difficile
- PLACIDE (2013): Probiotics to prevent CDAD
Colorectal Cancer
- COLONPREV (2012): FIT vs. colonoscopy for colon cancer screening
- NordICC (2022): Invitations for screening colonoscopy
Coronary Artery Disease
- CARP (2004): Preop coronary revascularization if stable CAD
- JUPITER (2008): Rosuvastatin for primary CV prevention
- MRFIT (1982): CHD risk modification for CHD mortality prevention
HIV
- IPrEx (2010): ART in primary HIV prevention
Hyperlipidemia
- JUPITER (2008): Rosuvastatin for primary CV prevention
Hypertension
Lung Cancer
- NLST (2011): CT vs. CXR in lung cancer screening
Neural Tube Defects
- Hungarian Prenatal Vitamin Trial (1992): Perinatal vitamins to prevent neural tube defects
Osteoporosis
- HORIZON-PFT (2007): Zoledronate vs. placebo in osteoporosis
Prostate Cancer
- ERSPC (2009): PSA for prostate cancer screening
Stroke
- JUPITER (2008): Rosuvastatin for primary CV prevention
Tobacco Abuse
- Cytisine for Smoking Cessation (2014): Cytisine vs. NRT for tobacco abuse
Transient Ischemic Attack
- JUPITER (2008): Rosuvastatin for primary CV prevention
Unplanned Pregnancy
- CHOICE (2014): Free long-acting reversible contraception in teens
Psychiatry
Acute Coronary Syndrome
- SADHART (2002): Sertraline for depression post-ACS
Alcohol Withdrawal
- Symptom-Triggered Benzodiazepines in Alcohol Withdrawal (2002): Symptom-triggered therapy in alcohol withdrawal
Alzheimer Disease
- CATIE-AD (2006): Antipsychotics in dementia with psychosis
Critical Illness
- MIND-USA (2018): Antipsychotics in ICU delirium
Delirium
- DELIRIA-J (2014): Ramelteon vs. placebo to prevent delirium
- MIND-USA (2018): Antipsychotics in ICU delirium
Dementia
- CATIE-AD (2006): Antipsychotics in dementia with psychosis
Depression
- ANTLER (2021): Maintenance vs. discontinuation of antidepressants
- Can-SAD (2006): Light therapy vs. SSRI for SAD
- SADHART (2002): Sertraline for depression post-ACS
- STAR-D (2006): Tiered approach for depression
Psychosis
- CATIE-AD (2006): Antipsychotics in dementia with psychosis
Schizophrenia
- CATIE (2005): Antipsychotics in schizophrenia
Seasonal Affective Disorder
- Can-SAD (2006): Light therapy vs. SSRI for SAD
Pulmonology
Acute Respiratory Distress Syndrome
- OSCILLATE (2013): High-frequency oscillatory vent in early ARDS
Asthma
- AMAZES (2017): Azithromycin in chronic asthma
- BASALT (2012): Symptom-based asthma therapy
- EXTRA (2011): Omalizumab in severe allergic asthma
- Novel START (2019): ICS+LABA PRN in mild asthma
- SMART (2006): Salmeterol in asthma
- TALC (2010): Tiotropium vs. others in asthma
Chronic Bronchitis
- FLAME (COPD) (2016): LABA+LAMA vs. LABA+ICS in COPD
Chronic Obstructive Pulmonary Disease
- FLAME (COPD) (2016): LABA+LAMA vs. LABA+ICS in COPD
- NETT (2003): Lung volume reduction in COPD
- NOTT (1980): Continuous vs. nocturnal oxygen in COPD
- REDUCE (2013): 5d vs. 14d steroids in acute COPD
- TORCH (2007): Salmeterol/fluticasone in COPD
- UPLIFT (2008): Tiotropium in COPD
- WISDOM (2014): ICS withdrawal in COPD
Critical Illness
- Yang-Tobin Study (1991): RSBI for predicting weaning
Deep Vein Thrombosis
- AMPLIFY (2013): Apixaban vs. warfarin in VTE
- PREPIC (1998): IVC filters for proximal DVT
- RE-COVER (2009): Dabigatran vs. warfarin in VTE
Emphysema
- FLAME (COPD) (2016): LABA+LAMA vs. LABA+ICS in COPD
- NETT (2003): Lung volume reduction in COPD
Hypoxemic Respiratory Failure
- FLORALI (2015): High-flow oxygen in respiratory failure
Idiopathic Pulmonary Fibrosis
- INPULSIS Trials (2014): Nintedanib in IPF
Lung Cancer
- NLST (2011): CT vs. CXR in lung cancer screening
- Twice-daily RT for SCLC (1999): Twice-daily RT in limited SCLC
Pleural Infection
- MIST2 (2011): tPA and/or DNase for pleural infection
Pneumonia
- 3C (2017): Antibiotic strategies in lower respiratory tract infections
- CAPE COD (2023): Hydrocortisone in severe CAP
- PneumA (2003): 8 vs. 15 days of antibiotics in VAP
Pulmonary Embolism
- AMPLIFY (2013): Apixaban vs. warfarin in VTE
- EINSTEIN-PE (2012): Rivaroxaban vs. warfarin in PE
- MOPETT (2013): Low-dose tPA for submassive PE
- PEITHO (2014): tPA for submassive PE
- PERC (2008): PE rule-out criteria
- PIOPED II (2006): Accuracy of CT for PE
- PREPIC (1998): IVC filters for proximal DVT
- RE-COVER (2009): Dabigatran vs. warfarin in VTE
Pulmonary Fibrosis
- ASCEND (IPF) (2014): Pirfenidone in IPF
Respiratory Failure
- Daily ICU Sedation Holidays (2000): Scheduled daily sedation holidays in intubated patients
Sepsis
- Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock (2017): Hydrocortisone, Vit C, and thiamine in sepsis
Shock
- Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock (2017): Hydrocortisone, Vit C, and thiamine in sepsis
Tobacco Abuse
- Cytisine for Smoking Cessation (2014): Cytisine vs. NRT for tobacco abuse
Venous Thromboembolism
- AMPLIFY (2013): Apixaban vs. warfarin in VTE
- EINSTEIN-PE (2012): Rivaroxaban vs. warfarin in PE
- MOPETT (2013): Low-dose tPA for submassive PE
- PEITHO (2014): tPA for submassive PE
- PIOPED II (2006): Accuracy of CT for PE
- PREPIC (1998): IVC filters for proximal DVT
- PREPIC 2 (2015): IVC filters for high-risk PE
- RE-COVER (2009): Dabigatran vs. warfarin in VTE
Radiation Oncology
Lung Cancer
- Twice-daily RT for SCLC (1999): Twice-daily RT in limited SCLC
Radiology
Abdominal Aortic Aneurysm
- MASS (2009): US screening for AAA in men
Spinal Stenosis
- LESS (2014): Epidural steroids in spinal stenosis
Rheumatology
ANCA-Associated Vasculitis
- RITUXVAS (2010): Rituximab in ANCA-Renal Vasculitis
Antiphospholipid Syndrome
- TRAPS (2018): Rivaroxaban in high-risk APLS
Coronary Artery Disease
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
Lupus
- ALMS (2009): MMF vs. CTX in lupus nephritis
Lupus Nephritis
- ALMS (2009): MMF vs. CTX in lupus nephritis
Osteoarthritis
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
Renal Vasculitis
- RITUXVAS (2010): Rituximab in ANCA-Renal Vasculitis
Rheumatoid Arthritis
- BeSt (2005): DMARD ± prednisone or infliximab in RA
- CAMERA (2007): Methotrexate strategies in RA
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
- TICORA (2004): Intensive vs. standard treatment in early RA
Stroke
- PRECISION (2016): Celecoxib, naproxen, or ibuprofen for CV safety in arthritis
Vasculitis
- CYCLOPS (2009): Pulse cyclophosphamide for ANCA vasculitis
- RAVE (2010): Rituximab vs. cyclophosphamide in ANCA-associated vasculitis
- RITUXVAS (2010): Rituximab in ANCA-Renal Vasculitis
Surgery
Anemia
- FOCUS (2011): Transfusion thresholds after hip surgery
- TRICS III (2017): Transfusion thresholds for cardiac surgery
Appendicitis
- APPAC (2015): Antibiotics vs. surgery for acute appendicitis
Breast Cancer
- ACOSOG Z0011 (2011): ALND in SLND-positive breast cancer
Cardiac Risk Assessment
- POISE (2008): Perioperative metoprolol
- POISE-2 ASA (2014): Perioperative ASA
Carotid Stenosis
- CREST (2010): Stenting vs. CEA in carotid stenosis
- ECST (1998): CEA in symptomatic carotid stenosis
- NASCET (1998): CEA in symptomatic carotid stenosis
Chronic Obstructive Pulmonary Disease
- NETT (2003): Lung volume reduction in COPD
Coronary Artery Disease
Diabetes Mellitus
- STAMPEDE (2012): Gastric bypass vs. medical therapy for T2DM
Emphysema
- NETT (2003): Lung volume reduction in COPD
Endocarditis
- EASE (2012): Early surgery in endocarditis
Hip Fracture
- FOCUS (2011): Transfusion thresholds after hip surgery
Intracranial Hypertension
- RESCUEicp (2016): Craniectomy vs. medical care for intracranial hypertension
Melanoma
- MSLT-1 (2014): SLNB vs. surveillance in melanoma
Meniscal Tear
- METEOR (2013): Surgery vs. PT in OA with meniscal tear
Obesity
- STAMPEDE (2012): Gastric bypass vs. medical therapy for T2DM
Osteoarthritis
- METEOR (2013): Surgery vs. PT in OA with meniscal tear
- Moseley Trial (2002): Arthroscopy in knee OA
Pancreatitis
- PANTER (2010): Step-up approach to pancreatitis
Renal Cell Carcinoma
- SWOG 8949 (2001): Cytoreductive nephrectomy in metastatic RCC
Stroke
- CREST (2010): Stenting vs. CEA in carotid stenosis
- ECST (1998): CEA in symptomatic carotid stenosis
- NASCET (1998): CEA in symptomatic carotid stenosis
Transient Ischemic Attack
- CREST (2010): Stenting vs. CEA in carotid stenosis
Trauma
- CRASH-2 (2010): Tranexamic acid in trauma
Traumatic Brain Injury
- RESCUEicp (2016): Craniectomy vs. medical care for intracranial hypertension
Transfusion Medicine
Anemia
- TRICC (1999): Transfusion thresholds in ICU
Urology
Prostate Cancer
- ERSPC (2009): PSA for prostate cancer screening
- PCPT (2003): Finasteride for prostate cancer prophylaxis
Renal Cell Carcinoma
- SWOG 8949 (2001): Cytoreductive nephrectomy in metastatic RCC
Urinary Tract Infections
- S-HYDRACYST (2018): Water intake to prevent UTI